Empagliflozin Decreased Proteinuria in Patients with Glomerulonephritis without Diabetes: A Randomized Clinical Trial
Objective: Empagliflozin (EMPA) is a new class of hypoglycemic drugs acting as a sodium glucose co-transporter 2 inhibi tor. In addition to reducing blood sugar, cardiovascular complications, and mortality rate, EMPA also has kidney protective properties (such as reducing proteinuria, progression o...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Turkish Society of Nephrology
2025-10-01
|
| Saila: | Turkish Journal of Nephrology |
| Gaiak: | |
| Sarrera elektronikoa: | https://turkjnephrol.org/index.php/pub/article/view/1671 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|